Riptide Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists.
AI & Machine LearningBiotechDigital HealthMedical DevicesHalethorpe, US
Daniel Lunz(Executive Officer, Director)William Stevens(Executive Officer)Stephen Meltzer(Director)
BoardJohn Neiderhuber(Director)
Co-investorsEarly Light VenturesMaryland TEDCOTEDCOGaingels
Previse offers a data health monitor and financial technology tools that harmonize fragmented financial data across multiple systems, using no-code ERP connectors, payment automation, and configurable workflows and analytics.
AI & Machine LearningData & InfrastructureFintechLondon, GB
Philipp Schoenbucher(Founder)in
Co-investorsAugmentum FintechFounders FactoryReefknot InvestmentsSalica InvestmentsBessemer Venture PartnersGaingels+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.